The Allegations: Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo’s Phase 3 CagriSema Study on Obesity According to the complaint ...

The Allegations: Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo's Phase 3 CagriSema Study on Obesity According to the complaint ...

In December, the share price fell by around 20% following the announcement of trial results for their next-generation weight loss drug, CagriSema. On Friday, the stock, however, saw a much-needed ...

BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) stock, maintaining both their Outperform rating and a $105.00 price target. The endorsement comes in the wake of promising ...

Investors had dumped Novo shares in late December when data on a highly touted experimental Novo weight-loss shot called CagriSema fell far short of the expectations the company had set.

Twice in the past two months, investors have been disappointed by the numbers -- 22.7% average weight loss over 68 weeks for CagriSema, and 20.7% weight loss for a 72-week regimen of semaglutide 7 ...

Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...

REUTERS/Tom Little//File Photo · Reuters / Reuters The company disappointed with a previous product, CagriSema, which delivered similar results but is partly based on semaglutide, the same active ...

In late December, Novo Nordisk announced that its much anticipated next-generation obesity drug CagriSema had missed its target for patients to lose 25 per cent of their body weight in a late ...